Evaluating Circulating Tumor Cells in Breast Cancer Follow-up
Evaluation of Circulating Tumor Cells (CTC) Relevance in Breast Cancer Follow-up Using the ScreenCell Device
This study is testing a new way to track cancer cells in the blood of breast cancer patients to see how their condition changes during treatment.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 93 (estimated) |
| Ages | 18 Years and up |
| Sex | Female |
| Sponsor | ScreenCell Industry-sponsored |
| Locations | 1 site (Neuilly-sur-Seine) |
| Trial ID | NCT06807502 on ClinicalTrials.gov |
What this trial studies
This study focuses on the use of liquid biopsy to detect and quantify circulating tumor cells (CTCs) in patients with breast cancer. Utilizing ScreenCell technology, it aims to monitor the evolution of CTCs during the follow-up phase of breast cancer treatment. By identifying and characterizing these cells, the study seeks to provide insights into the stage and molecular characteristics of the cancer. Participants include those with metastatic and non-metastatic breast cancer, as well as healthy volunteers for comparison.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18 and older with either metastatic breast cancer or non-metastatic invasive breast cancer who have not yet received treatment.
Not a fit: Patients with other types of cancer or those who are pregnant or breastfeeding may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance the monitoring and management of breast cancer by providing noninvasive insights into tumor progression.
How similar studies have performed: Other studies utilizing liquid biopsy techniques have shown promise in cancer monitoring, suggesting potential success for this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
INCLUSION CRITERIA For all participants : * Female with age greater than or equal to 18 years For participants with metastatic breast cancer: \- Patient observed with metastatic breast cancer from the outset or metastatic fall from previously treated breast cancer with change of therapeutic line at the time of inclusion. For participants with non-metastatic invasive breast cancer: \- Patient observed with non-metastatic infiltrative breast cancer who had not received any treatment at the time of inclusion (naïve to any treatment) For healthy volunteers: * Participant free of any cancer at the time of inclusion, confirmed using a mammogram whose results must be satisfactory, done at the latest two years before inclusion * Participant with no history of cancer EXCLUSION CRITERIA For all participants: * Male * Age less than 18 years old * Refusal to participate or withdrawal of consent * Pregnant and/or breastfeeding women * Discovery of a cancerous pathology (other than breast cancer for patients) during participant follow-up. For healthy volunteers: * History of cancer * Detection of CTC (positive profile) during screening
Where this trial is running
Neuilly-sur-Seine
- CMC Ambroise Paré Hartmann — Neuilly-sur-Seine, France (Recruiting)
Study contacts
- Study coordinator: Jessica GROULT, Ph.D
- Email: jgroult@screencell.com
- Phone: 0033669645318
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.